Literature DB >> 7526826

Inhibition of myelin formation by HIV-1 gp120 in rat cerebral cortex culture.

J Kimura-Kuroda1, K Nagashima, K Yasui.   

Abstract

To study the role of HIV-1 gp120 in loss of myelin in HIV encephalopathy, the binding of gp120 to various types of neural cells and its effects on myelination were examined in rat primary brain culture. Double-staining of cultured cells with gp120 and specific antibodies for different neural cell types showed that gp120 bound to most of the galactocerebroside (GalC)-positive oligodendrocytes, a small population of type-2-like astrocytes and a few small neurons. Gp120 did not bind to type-1-like astrocytes, most neurons, or to macrophage/microglia. To assay myelination, cells were bathed in a myelination medium containing chick embryo extract and high glucose, with or without gp120. Seven days after the application, myelination in the culture was observed morphologically and by staining with anti-myelin basic protein (MBP) antibody, and was found to be significantly inhibited by the addition of gp120 (50-100 nM). The processes of oligodendrocytes were reduced in length and arborization relative to the control, but MBP production by oligodendrocytes was unaffected. These results show that gp120 can cause a functional disorder of oligodendrocytes and thus could underlie the diffuse loss of myelin sheaths of HIV encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526826     DOI: 10.1007/bf01311175

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  47 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 2.  Functional plasticity of microglia: a review.

Authors:  W J Streit; M B Graeber; G W Kreutzberg
Journal:  Glia       Date:  1988       Impact factor: 7.452

3.  Long-term culture of human oligodendrocytes. Isolation, growth and identification.

Authors:  S U Kim; Y Sato; D H Silberberg; D E Pleasure; L B Rorke
Journal:  J Neurol Sci       Date:  1983-12       Impact factor: 3.181

4.  Inhibition of in vitro peripheral myelin formation by monoclonal anti-galactocerebroside.

Authors:  B Ranscht; P M Wood; R P Bunge
Journal:  J Neurosci       Date:  1987-09       Impact factor: 6.167

5.  Human immunodeficiency virus (HIV) envelope and core proteins in CNS tissues of patients with the acquired immune deficiency syndrome (AIDS).

Authors:  H Budka
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

6.  AIDS subacute encephalitis. Identification of HIV-infected cells.

Authors:  R Vazeux; N Brousse; A Jarry; D Henin; C Marche; C Vedrenne; J Mikol; M Wolff; C Michon; W Rozenbaum
Journal:  Am J Pathol       Date:  1987-03       Impact factor: 4.307

7.  Cell-type-specific markers for distinguishing and studying neurons and the major classes of glial cells in culture.

Authors:  M C Raff; K L Fields; S I Hakomori; R Mirsky; R M Pruss; J Winter
Journal:  Brain Res       Date:  1979-10-05       Impact factor: 3.252

8.  In vivo CNS demyelination mediated by anti-galactocerebroside antibody.

Authors:  K Ozawa; T Saida; K Saida; H Nishitani; M Kameyama
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

9.  Periodic synchronized bursting and intracellular calcium transients elicited by low magnesium in cultured cortical neurons.

Authors:  H P Robinson; M Kawahara; Y Jimbo; K Torimitsu; Y Kuroda; A Kawana
Journal:  J Neurophysiol       Date:  1993-10       Impact factor: 2.714

View more
  9 in total

1.  HIV-1 gp120-induced axonal injury detected by accumulation of β-amyloid precursor protein in adult rat corpus callosum.

Authors:  Jingdong Zhang; Jianuo Liu; Bryan Katafiasz; Howard Fox; Huangui Xiong
Journal:  J Neuroimmune Pharmacol       Date:  2011-02-02       Impact factor: 4.147

Review 2.  HIV-1 infection alters energy metabolism in the brain: Contributions to HIV-associated neurocognitive disorders.

Authors:  Bianca Cotto; Kalimuthusamy Natarajanseenivasan; Dianne Langford
Journal:  Prog Neurobiol       Date:  2019-05-18       Impact factor: 11.685

3.  Human immunodeficiency virus protein Tat induces oligodendrocyte injury by enhancing outward K+ current conducted by KV1.3.

Authors:  Han Liu; Jianuo Liu; Enquan Xu; Guihua Tu; Minglei Guo; Shangdong Liang; Huangui Xiong
Journal:  Neurobiol Dis       Date:  2016-11-02       Impact factor: 5.996

Review 4.  Bromodomains in Human-Immunodeficiency Virus-Associated Neurocognitive Disorders: A Model of Ferroptosis-Induced Neurodegeneration.

Authors:  Adonis Sfera; Karina G Thomas; Christina V Andronescu; Nyla Jafri; Dan O Sfera; Sarvin Sasannia; Carlos M Zapata-Martín Del Campo; Jose C Maldonado
Journal:  Front Neurosci       Date:  2022-05-12       Impact factor: 5.152

5.  Human immunodeficiency virus-1 uses the mannose-6-phosphate receptor to cross the blood-brain barrier.

Authors:  Shinya Dohgu; Jan S Ryerse; Sandra M Robinson; William A Banks
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

6.  HIV-induced neuroinflammation inhibits oligodendrocyte maturation via glutamate-dependent activation of the PERK arm of the integrated stress response.

Authors:  Lindsay M Roth; Cagla Akay-Espinoza; Judith B Grinspan; Kelly L Jordan-Sciutto
Journal:  Glia       Date:  2021-05-31       Impact factor: 8.073

7.  EXPRESS: Oligodendrocytes in HIV-associated pain pathogenesis.

Authors:  Yuqiang Shi; Jianghong Shu; Zongsuo Liang; Subo Yuan; Shao-Jun Tang
Journal:  Mol Pain       Date:  2016-06-15       Impact factor: 3.395

Review 8.  Oligodendrocyte Injury and Pathogenesis of HIV-1-Associated Neurocognitive Disorders.

Authors:  Han Liu; Enquan Xu; Jianuo Liu; Huangui Xiong
Journal:  Brain Sci       Date:  2016-07-22

Review 9.  Opioid and neuroHIV Comorbidity - Current and Future Perspectives.

Authors:  Sylvia Fitting; MaryPeace McRae; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-02       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.